Tirosin kinase inhibitors in chronic graft versus host disease: From bench to bedside

TheScientificWorldJournal

Volumn 11, Issue , 2011, Pages 1908-1931

  Olivieri, Jacopo ^a   Coluzzi, Sabrina ^b   Attolico, Imma ^b   Olivieri, Attilio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b SAN CARLO HOSPITAL   (Italy)

Author keywords

cGVHD; Imatinib; TKI

Indexed keywords

CORTICOSTEROID; DASATINIB; IMATINIB; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NILOTINIB; PENTOSTATIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOPENIA; DECOMPOSITION; DENDRITIC CELL; DIABETES MELLITUS; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; EXTRACORPOREAL CIRCULATION; FATIGUE; FIBROSING ALVEOLITIS; FLUID RETENTION; HEADACHE; HEART FAILURE; HEPATITIS; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFECTION; INJECTION SITE REACTION; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MYALGIA; NAUSEA; NEUROTOXICITY; NONHUMAN; PSYCHOSIS; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 81555223016     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/2011/924954     Document Type: Article

References (168)

1. Lee S. J., Vogelsang G., Flowers M. E. D., Chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2003 9 4 215 233 (Pubitemid 40045609)
2. Filipovich A. H., Weisdorf D., Pavletic S., Socie G., Wingard J. R., Lee S. J., Martin P., Chien J., Przepiorka D., Couriel D., Cowen E. W., Dinndorf P., Farrell A., Hartzman R., Henslee-Downey J., Jacobsohn D., McDonald G., Mittleman B., Rizzo J. D., Robinson M., Schubert M., Schultz K., Shulman H., Turner M., Vogelsang G., Flowers M. E. D., National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report Biology of Blood and Marrow Transplantation 2005 11 12 945 956 (Pubitemid 41754712)
3. Lee S. J., Flowers M. E., Recognizing and managing chronic graft-versus-host disease Hematology 2008 134 141
4. Shulman H. M., Kleiner D., Lee S. J., Morton T., Pavletic S. Z., Farmer E., Moresi J. M., Greenson J., Janin A., Martin P. J., McDonald G., Flowers M. E. D., Turner M., Atkinson J., Lefkowitch J., Washington M. K., Prieto V. G., Kim S. K., Argenyi Z., Diwan A. H., Rashid A., Hiatt K., Couriel D., Schultz K., Hymes S., Vogelsang G. B., Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. Pathology working group report Biology of Blood and Marrow Transplantation 2006 12 1 31 47 (Pubitemid 43034096)
5. Lee S. J., Have we made progress in the management of chronic graft-vs-host disease? Best Practice and Research 2010 23 4 529 535
6. Bhatia S., Francisco L., Carter A., Sun C. L., Baker K. S., Gurney J. G., McGlave P. B., Nademanee A., O'Donnell M., Ramsay N. K. C., Robison L. L., Snyder D., Stein A., Forman S. J., Weisdorf D. J., Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor study Blood 2007 110 10 3784 3792 (Pubitemid 350159650)
7. Flowers M. E. D., Inamoto Y., Carpenter P. A., Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria Blood 2011 117 3214 3219
8. Billingham R. E., The biology of graft-versus-host reactions Harvey Lectures 1966 62 21 78
9. Ferrara J. L. M., Antin J. H., Blume K. G., Forman S. J., Appelbaum F. R., The pathophysiology of graft-vs.-host disease Thomas' Hematopoietic Cell Transplantation 2004 3rd Malden, Mass, USA Blackwell Publishing 353 368
10. Ferrara J. L., Levine J. E., Reddy P., Holler E., Graft-versus-host disease The Lancet 2009 373 9674 1550 1561
11. Schroeder M. A., DiPersio J. F., Mouse models of graft-versus-host disease: advances and limitations Disease Models Mechanisms 2011 4 318 333
12. Chu Y. W., Gress R. E., Murine models of chronic graft-versus-host disease: insights and unresolved issues Biology of Blood and Marrow Transplantation 2008 14 4 365 378
13. Martin P. J., Biology of chronic graft-versus-host disease: implications for a future therapeutic approach Keio Journal of Medicine 2008 57 4 177 183
14. Toubai T., Sun Y., Reddy P., GVHD pathophysiology: is acute different from chronic? Best Practice Research Clinical Haematology 2008 21 2 101 117 (Pubitemid 351712711)
15. Korngold R., Sprent J., Lethal graft versus host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow Journal of Experimental Medicine 1978 148 6 1687 1698 (Pubitemid 9084041)
16. Aversa F., Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States Bone Marrow Transplantation 2008 41 5 473 481 (Pubitemid 351386712)
17. Teshima T., Wynn T. A., Soiffer R. J., Matsuoka K. I., Martin P. J., Chronic graft-versus-host disease: how can we release Prometheus? Biology of Blood and Marrow Transplantation 2008 14 supplement 1 142 150
18. Tyndall A., Dazzi F., Chronic GVHD as an autoimmune disease Best Practice and Research Clinical Haematology 2008 21 2 281 289 (Pubitemid 351712722)
19. Rozendaal L., Pals S. T., Gleichmann E., Melief C. J. M., Persistence of allospecific helper T cells is required for maintaining autoantibody formation in lupus-like graft-versus-host disease Clinical and Experimental Immunology 1990 82 3 527 532
20. Fukushi N., Arase H., Wang B., Ogasawara K., Gotohda T., Good R. A., Onoé K., Thymus: a direct target tissue in graft-versus-host reaction after allogeneic bone marrow transplantation that results in abrogation of induction of self-tolerance Proceedings of the National Academy of Sciences of the United States of America 1990 87 16 6301 6305
21. Ghayur T., Seemayer T. A., Xenocostas A., Lapp W. S., Complete sequential regeneration of graft-vs.-host-induced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease American Journal of Pathology 1988 133 1 39 46
22. Krenger W., Hollnder G. A., The immunopathology of thymic GVHD Seminars in Immunopathology 2008 30 4 439 456
23. Sakoda Y., Hashimoto D., Asakura S., Takeuchi K., Harada M., Tanimoto M., Teshima T., Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood 2007 109 4 1756 1764 (Pubitemid 46239612)
24. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J. E., Roncarolo M. G., A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis Nature 1997 389 6652 737 742 (Pubitemid 27458961)
25. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3 Science 2003 299 5609 1057 1061 (Pubitemid 36222930)
26. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S. I., Nanan R., Kelleher A., De S. G. B. F., Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells Journal of Experimental Medicine 2006 203 7 1693 1700 (Pubitemid 44036275)
27. Roncarolo M. G., Battaglia M., Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans Nature Reviews Immunology 2007 7 8 585 598 (Pubitemid 47123554)
28. Rezvani K., Mielke S., Ahmadzadeh M., Kilical Y., Savani B. N., Zeilah J., Keyvanfar K., Montero A., Hensel N., Kurlander R., Barrett A. J., High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT Blood 2006 108 4 1291 1297 (Pubitemid 44232027)
29. Zorn E., Kim H. T., Lee S. J., Floyd B. H., Litsa D., Arumugarajah S., Bellucci R., Alyea E. P., Antin J. H., Soiffer R. J., Ritz J., Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease Blood 2005 106 8 2903 2911 (Pubitemid 41510772)
30. Miura Y., Thoburn C. J., Bright E. C., Phelps M. L., Shin T., Matsui E. C., Matsui W. H., Arai S., Fuchs E. J., Vogelsang G. B., Jones R. J., Hess A. D., Association of Foxp3 regulatory gene expression with graft-versus-host disease Blood 2004 104 7 2187 2193 (Pubitemid 39297878)
31. Clark F. J., Gregg R., Piper K., Dunnion D., Freeman L., Griffiths M., Begum G., Mahendra P., Craddock C., Moss P., Chakraverty R., Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells Blood 2004 103 6 2410 2416 (Pubitemid 38326268)
32. Rieger K., Loddenkemper C., Maul J., Fietz T., Wolff D., Terpe H., Steiner B., Berg E., Miehlke S., Bornhuser M., Schneider T., Zeitz M., Stein H., Thiel E., Duchmann R., Uharek L., Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD Blood 2006 107 4 1717 1723 (Pubitemid 43242414)
33. Trzonkowski P., Bieniaszewska M., Juscinska J., Dobyszuk A., Krzystyniak A., Marek N., Myliwska J., Hellmann A., First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells Clinical Immunology 2009 133 1 22 26
34. Shimabukuro-Vornhagen A., Hallek M. J., Storb R. F., von Bergwelt-Baildon M. S., The role of B cells in the pathogenesis of graft-versus-host disease Blood 2009 114 24 4919 4927
35. Kapur R., Ebeling S., Hagenbeek A., B-cell involvement in chronic graft-versus-host disease Haematologica 2008 93 11 1702 1711
36. Zorn E., Miklos D. B., Floyd B. H., Mattes-Ritz A., Guo L., Soiffer R. J., Antin J. H., Ritz J., Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation Journal of Experimental Medicine 2004 199 8 1133 1142 (Pubitemid 38619909)
37. Miklos D. B., Kim H. T., Miller K. H., Guo L., Zorn E., Lee S. J., Hochberg E. P., Wu C. J., Alyea E. P., Cutler C., Ho V., Soiffer R. J., Antin J. H., Ritz J., Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission Blood 2005 105 7 2973 2978 (Pubitemid 40446295)
38. Svegliati S., Olivieri A., Campelli N., Luchetti M., Poloni A., Trappolini S., Moroncini G., Bacigalupo A., Leoni P., Avvedimento E. V., Gabrielli A., Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease Blood 2007 110 1 237 241 (Pubitemid 47026840)
39. Thien M., Phan T. G., Gardam S., Amesbury M., Basten A., MacKay F., Brink R., Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches Immunity 2004 20 6 785 798 (Pubitemid 38757447)
40. Sarantopoulos S., Stevenson K. E., Kim H. T., Bhuiya N. S., Cutler C. S., Soiffer R. J., Antin J. H., Ritz J., High levels of B-cell activating factor in patients with active chronic graft-versus-host disease Clinical Cancer Research 2007 13 20 6107 6114 (Pubitemid 350075069)
41. Sarantopoulos S., Stevenson K. E., Kim H. T., Cutler C. S., Bhuiya N. S., Schowalter M., Ho V. T., Alyea E. P., Koreth J., Blazar B. R., Soiffer R. J., Antin J. H., Ritz J., Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease Blood 2009 113 16 3865 3874
42. She K., Gilman A. L., Aslanian S., Shimizu H., Krailo M., Chen Z., Reid G. S., Wall D., Goldman F., Schultz K. R., Altered Toll-like receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2007 13 4 386 397 (Pubitemid 46421893)
43. Gabrielli A., Avvedimento E. V., Krieg T., Scleroderma The New England Journal of Medicine 2009 360 19 1989 2003
44. Skert C., Patriarca F., Sperotto A., Cerno M., Fil C., Zaja F., Stocchi R., Geromin A., Damiani D., Fanin R., Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome Haematologica 2006 91 2 258 261
45. Jaffee B. D., Claman H. N., Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems Cellular Immunology 1983 77 1 1 12 (Pubitemid 13135593)
46. DeClerck Y., Draper V., Parkman R., Clonal analysis of murine graft-vs-host disease. II leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs. host disease Journal of Immunology 1986 136 10 3549 3552 (Pubitemid 16122044)
47. McCormick L. L., Zhang Y., Tootell E., Gilliam A. C., Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma Journal of Immunology 1999 163 10 5693 5699
48. Zhang Y., McCormick L. L., Gilliam A. C., Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation Journal of Immunology 2002 168 6 3088 3098 (Pubitemid 34211692)
49. Zhang Y., McCormick L. L., Gilliam A. C., Latency-associated peptide prevents skin fibrosis in murine sclerodermatous graft-versus-host disease, a model for human scleroderma Journal of Investigative Dermatology 2003 121 4 713 719 (Pubitemid 37239112)
50. Baroni S. S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., Fraticelli P., Sambo P., Funaro A., Kazlauskas A., Avvedimento E. V., Gabrielli A., Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis The New England Journal of Medicine 2006 354 25 2667 2676
51. Smaldone S., Olivieri J., Gusella G. L., Moroncini G., Gabrielli A., Ramirez F., Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts Fibrogenesis Tissue Repair 2011 4, article 8
52. Wolff D., Gerbitz A., Ayuk F., Kiani A., Hildebrandt G. C., Vogelsang G. B., Elad S., Lawitschka A., Socie G., Pavletic S. Z., Holler E., Greinix H., Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD Biology of Blood and Marrow Transplantation 2010 16 12 1611 1628
53. Vogelsang G. B., How I treat chronic graft-versus-host disease Blood 2001 97 5 1196 1201 (Pubitemid 32183739)
54. Koc S., Leisenring W., Flowers M. E. D., Anasetti C., Deeg H. J., Nash R. A., Sanders J. E., Witherspoon R. P., Storb R., Appelbaum F. R., Martin P. J., Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone Blood 2002 100 1 48 51 (Pubitemid 35177427)
55. Baird K., Cooke K., Schultz K. R., Chronic graft-versus-host disease (GVHD) in children Pediatric Clinics of North America 2010 57 1 297 322
56. Socie G., Ritz J., Martin P. J., Current challenges in chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2010 16 supplement 1 S146 S151
57. Wolff D., Schleuning M., von Harsdorf S., Bacher U., Gerbitz A., Stadler M., Ayuk F., Kiani A., Schwerdtfeger R., Vogelsang G. B., Kobbe G., Gramatzki M., Lawitschka A., Mohty M., Pavletic S. Z., Greinix H., Holler E., Consensus conference on clinical practice in chronic GVHD: second-line Treatment of chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2010 17 1 17
58. Berger M., Biasin E., Saglio F., Fagioli F., Innovative approaches to treat steroid-resistant or steroid refractory GVHD Bone Marrow Transplantation 2008 42 supplement 2 S101 S105
59. Cutler C., Miklos D., Kim H. T., Treister N., Woo S. B., Bienfang D., Klickstein L. B., Levin J., Miller K., Reynolds C., Macdonell R., Pasek M., Lee S. J., Ho V., Soiffer R., Antin J. H., Ritz J., Alyea E., Rituximab for steroid-refractory chronic graft-versus-host disease Blood 2006 108 2 756 762 (Pubitemid 44061381)
60. Carella A. M., Biasco S., Nati S., Congiu A., Lerma E., Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease Leukemia and Lymphoma 2007 48 3 623 624 (Pubitemid 46487774)
61. Mohty M., Marchetti N., El Cheikh J., Faucher C., Furst S., Blaise D., Rituximab as salvage therapy for refractory chronic GVHD Bone Marrow Transplantation 2008 41 10 909 911 (Pubitemid 351761695)
62. Okamoto M., Okano A., Akamatsu S., Ashihara E., Inaba T., Takenaka H., Katoh N., Kishimoto S., Shimazaki C., Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease Leukemia 2006 20 1 172 173
63. Teshima T., Nagafuji K., Henzan H., Miyamura K., Takase K., Hidaka M., Miyamoto T., Takenaka K., Akashi K., Harada M., Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease International Journal of Hematology 2009 90 2 253 260
64. Canninga-Van Dijk M. R., van der Straaten H. M., Fijnheer R., Sanders C. J., Van Den Tweel J. G., Verdonck L. F., Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease Blood 2004 104 8 2603 2606 (Pubitemid 39331867)
65. Ratanatharathorn V., Ayash L., Reynolds C., Silver S., Reddy P., Becker M., Ferrara J. L. M., Uberti J. P., Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody Biology of Blood and Marrow Transplantation 2003 9 8 505 511 (Pubitemid 38351794)
66. Zaja F., Bacigalupo A., Patriarca F., Stanzani M., Van Lint M. T., Fil C., Scim R., Milone G., Falda M., Vener C., Laszlo D., Alessandrino P. E., Narni F., Sica S., Olivieri A., Sperotto A., Bosi A., Bonifazi F., Fanin R., Treatment of refractory chronic GVHD with rituximab: a GITMO study Bone Marrow Transplantation 2007 40 3 273 277 (Pubitemid 47108472)
67. Von Bonin M., Oelschlagel U., Radke J., Stewart M., Ehninger G., Bornhauser M., Platzbecker U., Treatment of chronic steroid-refractory graft-versus-host disease with low-dose rituximab Transplantation 2008 86 6 875 879
68. Kharfan-Dabaja M. A., Mhaskar A. R., Djulbegovic B., Cutler C., Mohty M., Kumar A., Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis Biology of Blood and Marrow Transplantation 2009 15 9 1005 1013
69. Couriel D. R., Hosing C., Saliba R., Shpall E. J., Anderlini P., Rhodes B., Smith V., Khouri I., Giralt S., De Lima M., Hsu Y., Ghosh S., Neumann J., Andersson B., Qazilbash M., Hymes S., Kim S., Champlin R., Donato M., Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD Blood 2006 107 8 3074 3080
70. Flowers M. E. D., Apperley J. F., van Besien K., Elmaagacli A., Grigg A., Reddy V., Bacigalupo A., Kolb H. J., Bouzas L., Michallet M., Prince H. M., Knobler R., Parenti D., Gallo J., Greinix H. T., A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease Blood 2008 112 7 2667 2674
71. Jacobsohn D. A., Chen A. R., Zahurak M., Piantadosi S., Anders V., Bolaos-Meade J., Higman M., Margolis J., Raup M., Vogelsang G. B., Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease Journal of Clinical Oncology 2007 25 27 4255 4261 (Pubitemid 47548565)
72. Mookerjee B., Altomonte V., Vogelsang G., Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus Bone Marrow Transplantation 1999 24 5 517 520 (Pubitemid 29423631)
73. Lopez F., Parker P., Nademanee A., Rodriguez R., Al-Kadhimi Z., Bhatia R., Cohen S., Falk P., Fung H., Kirschbaum M., Krishnan A., Kogut N., Molina A., Nakamura R., O'Donnell M., Popplewell L., Pullarkat V., Rosenthal J., Sahebi F., Smith E., Snyder D., Somlo G., Spielberger R., Stein A., Sweetman R., Zain J., Forman S., Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2005 11 4 307 313 (Pubitemid 40450758)
74. Busca A., Locatelli F., Marmont F., Audisia E., Falda M., Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease Haematologica 2003 88 7 837 839 (Pubitemid 36890123)
75. Akpek G., Lee S. M., Anders V., Vogelsang G. B., A high-dose pulse steroid regimen for controlling active chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2001 7 9 495 502 (Pubitemid 32979135)
76. Kanamaru A., Takemoto Y., Kakishita E., Dohy H., Kodera Y., Moriyama Y., Shibata A., Kasai M., Katoh S., Saitoh H., Matsuda T., Hattori M., Okamoto S., Asano S., Horiuchi A., Harada M., Hiraoka A., Masaoka T., FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Japanese FK506 BMT study group Bone Marrow Transplantation 1995 15 6 885 889
77. Couriel D. R., Saliba R., Escalan M. P., Hsu Y., Ghosh S., Ippoliti C., Hicks K., Donato M., Giralt S., Khouri I. F., Hosing C., De Lima M. J., Andersson B., Neumann J., Champlin R., Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease British Journal of Haematology 2005 130 3 409 417 (Pubitemid 43899590)
78. Johnston L. J., Brown J., Shizuru J. A., Stockerl-Goldstein K. E., Stuart M. J., Blume K. G., Negrin R. S., Chao N. J., Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease Biology of Blood and Marrow Transplantation 2005 11 1 47 55 (Pubitemid 40057993)
79. Greinix H. T., Volc-Platzer B., Kalhs P., Fischer G., Rosenmayr A., Keil F., Honigsmann H., Knobler R. M., Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study Blood 2000 96 7 2426 2431
80. Buchdunger E., Cioffi C. L., Law N., Stover D., Ohno-Jones S., Druker B. J., Lydon N. B., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors Journal of Pharmacology and Experimental Therapeutics 2000 295 1 139 145
81. Heinrich M. C., Corless C. L., Duensing A., McGreevey L., Chen C. J., Joseph N., Singer S., Griffith D. J., Haley A., Town A., Demetri G. D., Fletcher C. D. M., Fletcher J. A., PDGFRA activating mutations in gastrointestinal stromal tumors Science 2003 299 5607 708 710 (Pubitemid 36159485)
82. Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D. M., Joensuu H., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors The New England Journal of Medicine 2002 347 7 472 480 (Pubitemid 34879334)
83. Hunter T., Treatment for chronic myelogenous leukemia: the long road to imatinib Journal of Clinical Investigation 2007 117 8 2036 2043 (Pubitemid 47219543)
84. Ustun C., Deremer D. L., Akin C., Tyrosine kinase inhibitors in the treatment of systemic mastocytosis Leukemia Research 2011 35 9 1143 1152
85. Druker B. J., Guilhot F., O'Brien S. G., Gathmann I., Kantarjian H., Gattermann N., Deininger M. W. N., Silver R. T., Goldman J. M., Stone R. M., Cervantes F., Hochhaus A., Powell B. L., Gabrilove J. L., Rousselot P., Reiffers J., Cornelissen J. J., Hughes T., Agis H., Fischer T., Verhoef G., Shepherd J., Saglio G., Gratwohl A., Nielsen J. L., Radich J. P., Simonsson B., Taylor K., Baccarani M., So C., Letvak L., Larson R. A., Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia The New England Journal of Medicine 2006 355 23 2408 2417 (Pubitemid 44903745)
86. Hochhaus A., Druker B., Sawyers C., Guilhot F., Schiffer C. A., Cortes J., Niederwieser D. W., Gambacorti C., Stone R. M., Goldman J., Fischer T., O'Brien S. G., Reiffers J. J., Mone M., Krahnke T., Talpaz M., Kantarjian H. M., Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment Blood 2008 111 3 1039 1043 (Pubitemid 351213381)
87. Cohen M. H., Johnson J. R., Pazdur R., U.S. food and drug administration drug approval summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval Clinical Cancer Research 2005 11 1 12 19 (Pubitemid 40075773)
88. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F. J., Rosenzweig A., Salomon R. N., Van Etten R. A., Alroy J., Durand J. B., Force T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine 2006 12 8 908 916 (Pubitemid 44175142)
89. Gambacorti C., Tornaghi L., Franceschino A., Piazza R., Corneo G., Pogliani E., In reply to cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine 2007 13 1 13 14 (Pubitemid 46067369)
90. Hatfield A., Owen S., Pilot P. R., In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' Nature Medicine 2007 13 1 13 16
91. Atallah E., Durand J. B., Kantarjian H., Cortes J., Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 2007 110 4 1233 1237 (Pubitemid 47281421)
92. Burke M. J., Trotz B., Luo X., Weisdorf D. J., Baker K. S., Wagner J. E., Verneris M. R., Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients Bone Marrow Transplantation 2009 44 3 169 174
93. Giles F. J., O'Dwyer M., Swords R., Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia Leukemia 2009 23 10 1698 1707
94. Kantarjian H., Giles F., Wunderle L., Bhalla K., O'Brien S., Wassmann B., Tanaka C., Manley P., Rae P., Mietlowski W., Bochinski K., Hochhaus A., Griffin J. D., Hoelzer D., Albitar M., Dugan M., Cortes J., Alland L., Ottmann O. G., Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL The New England Journal of Medicine 2006 354 24 2542 2551 (Pubitemid 43882350)
95. Anderlini P., Sheth S., Hicks K., Ippoliti C., Giralt S., Champlin R. E., Re: imatinib mesylate administration in the first 100 days after stem cell transplantation Biology of Blood and Marrow Transplantation 2004 10 12 883 884 (Pubitemid 39625310)
96. Carpenter P. A., Snyder D. S., Flowers M. E. D., Sanders J. E., Gooley T. A., Martin P. J., Appelbaum F. R., Radich J. P., Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia Blood 2007 109 7 2791 2793 (Pubitemid 46482072)
97. Olivieri A., Manzione L., Dasatinib: a new step in molecular target therapy Annals of Oncology 2007 18 supplement 6 542 546
98. Ottmann O., Dombret H., Martinelli G., Simonsson B., Guilhot F., Larson R. A., Rege-Cambrin G., Radich J., Hochhaus A., Apanovitch A. M., Gollerkeri A., Coutre S., Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood 2007 110 7 2309 2315 (Pubitemid 47523149)
99. Khoury H. J., Guilhot F., Hughes T. P., Kim D. W., Cortes J. E., Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations Cancer 2009 115 7 1381 1394
100. Weisberg E., Manley P. W., Breitenstein W., Brggen J., Cowan-Jacob S. W., Ray A., Huntly B., Fabbro D., Fendrich G., Hall-Meyers E., Kung A. L., Mestan J., Daley G. Q., Callahan L., Catley L., Cavazza C., Mohammed A., Neuberg D., Wright R. D., Gilliland D. G., Griffin J. D., Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 2005 7 2 129 141 (Pubitemid 40248339)
101. Merante S., Colombo A. A., Calatroni S., Rocca B., Boni M., Bernasconi P., Bonvini L., Soverini S., Alessandrino E. P., Nilotinib restores long-term full-donor chimerism in Ph-positive acute lymphoblastic leukemia relapsed after allogeneic transplantation Bone Marrow Transplantation 2009 44 4 263 264
102. Boschelli F., Arndt K., Gambacorti-Passerini C., Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia European Journal of Cancer 2010 46 10 1781 1789
103. Zipfel P. A., Zhang W., Quiroz M., Pendergast A. M., Requirement for Abl kinases in T cell receptor signaling Current Biology 2004 14 14 1222 1231 (Pubitemid 38991808)
104. Zipfel P. A., Grove M., Blackburn K., Fujimoto M., Tedder T. F., Pendergast A. M., The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19 Journal of Immunology 2000 165 12 6872 6879 (Pubitemid 32001156)
105. Tybulewicz V. L. J., Crawford C. E., Jackson P. K., Bronson R. T., Mulligan R. C., Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene Cell 1991 65 7 1153 1163 (Pubitemid 121001329)
106. Agosti V., Corbacioglu S., Ehlers I., Waskow C., Sommer G., Berrozpe G., Kissel H., Tucker C. M., Manova K., Moore M. A. S., Rodewald H. R., Besmer P., Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development Journal of Experimental Medicine 2004 199 6 867 878 (Pubitemid 38375206)
107. Miyachi K., Ihara A., Hankins R. W., Murai R., Maehiro S., Miyashita H., Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia Clinical Rheumatology 2003 22 4-5 329 332 (Pubitemid 37483630)
108. Eklund K. K., Joensuu H., Treatment of rheumatoid arthritis with imatinib mesylate: clinical improvement in three refractory cases Annals of Medicine 2003 35 5 362 367 (Pubitemid 37013677)
109. Olivieri A., Cimminiello M., Locatelli F., Imatinib is safe and effective in patients with refractory Chronic Graft Versus Host Disease: analysis of two consecutive prospective GITMO studies Blood 2010 116, article 246
110. Paniagua R. T., Sharpe O., Ho P. P., Chan S. M., Chang A., Higgins J. P., Tomooka B. H., Thomas F. M., Song J. J., Goodman S. B., Lee D. M., Genovese M. C., Utz P. J., Steinman L., Robinson W. H., Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis Journal of Clinical Investigation 2006 116 10 2633 2642 (Pubitemid 44511627)
111. Dietz A. B., Souan L., Knutson G. J., Bulur P. A., Litzow M. R., Vuk-Pavlovi S., Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo Blood 2004 104 4 1094 1099 (Pubitemid 39038030)
112. Seggewiss R., Lore K., Greiner E., Magnusson M. K., Price D. A., Douek D. C., Dunbar C. E., Wiestner A., Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner Blood 2005 105 6 2473 2479 (Pubitemid 40387048)
113. Ho S., Clipstone N., Timmermann L., The mechanism of action of cyclosporin A and FK506 Clinical Immunology and Immunopathology 1996 80 3 S40 S45
114. Seggewiss R., Price D. A., Purbhoo M. A., Immunomodulatory effects of imatinib and second-generation tyrosine kinase inhibitors on T cells and dendritic cells: an update Cytotherapy 2008 10 6 633 641
115. Cwynarksi K., Laylor R., Macchiarulo E., Goldman J., Lombardi G., Melo J. V., Dazzi F., Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro Leukemia 2004 18 8 1332 1339 (Pubitemid 39136740)
116. Zamoyska R., Basson A., Filby A., Legname G., Lovatt M., Seddon B., The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation Immunological Reviews 2003 191 107 118 (Pubitemid 36398852)
117. Schade A. E., Schieven G. L., Townsend R., Jankowska A. M., Susulic V., Zhang R., Szpurka H., Maciejewski J. P., Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Blood 2008 111 3 1366 1377 (Pubitemid 351213423)
118. Das J., Chen P., Norris D., Padmanabha R., Lin J., Moquin R. V., Shen Z., Cook L. S., Doweyko A. M., Pitt S., Pang S., Shen D. R., Fang Q., De Fex H. F., McIntyre K. W., Shuster D. J., Gillooly K. M., Behnia K., Schieven G. L., Wityak J., Barrish J. C., 2-aminothiazole as a novel kinase inhibitor template Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl- 4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor Journal of Medicinal Chemistry 2006 49 23 6819 6832 (Pubitemid 44749749)
119. Weichsel R., Dix C., Wooldridge L., Clement M., Fenton-May A., Sewell A. K., Zezula J., Greiner E., Gostick E., Price D. A., Einsele H., Seggewiss R., Profound inhibition of antigen-specific T-cell effector functions by dasatinib Clinical Cancer Research 2008 14 8 2484 2491 (Pubitemid 351551084)
120. Larmonier N., Janikashvili N., Lacasse C. J., Larmonier C. B., Cantrell J., Situ E., Lundeen T., Bonnotte B., Katsanis E., Imatinib mesylate inhibits CD4+CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors Journal of Immunology 2008 181 10 6955 6963
121. Buchdunger E., Matter A., Druker B. J., Bcr-Abl inhibition as a modality of CML therapeutics Biochimica et Biophysica Acta 2001 1551 M11 M18 (Pubitemid 32831485)
122. Fabian M. A., Biggs W. H. III, Treiber D. K., Atteridge C. E., Azimioara M. D., Benedetti M. G., Carter T. A., Ciceri P., Edeen P. T., Floyd M., Ford J. M., Galvin M., Gerlach J. L., Grotzfeld R. M., Herrgard S., Insko D. E., Insko M. A., Lai A. G., Lélias J. M., Mehta S. A., Milanov Z. V., Velasco A. M., Wodicka L. M., Patel H. K., Zarrinkar P. P., Lockhart D. J., A small molecule-kinase interaction map for clinical kinase inhibitors Nature Biotechnology 2005 23 3 329 336 (Pubitemid 41094421)
123. Santachiara R., Maffei R., Martinelli S., Arcari A., Piacentini F., Trabacchi E., Alfieri P., Ferrari A., Leonardi G., Luppi G., Longo G., Vallisa D., Marasca R., Torelli G., Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor Haematologica 2008 93 8 1252 1255
124. Steegmann J. L., Moreno G., Alez C., Osorio S., Granda A., De la Cmara R., Arranz E., Gmez Reino F., Rodriguez Salvanés F., Fernndez-Raada J. M., Muoz C., Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia Haematologica 2003 88 7 762 768 (Pubitemid 36890110)
125. Napolitani G., Bortoletto N., Racioppi L., Lanzavecchia A., D'Oro U., Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation European Journal of Immunology 2003 33 10 2832 2841 (Pubitemid 37337149)
126. Chu C. L., Lowell C. A., The Lyn tyrosine kinase differentially regulates dendritic cell generation and maturation Journal of Immunology 2005 175 5 2880 2889 (Pubitemid 41170505)
127. Appel S., Boehmler A. M., Grnebach F., Mller M. R., Rupf A., Weck M. M., Hartmann U., Reichardt V. L., Kanz L., Brmmendorf T. H., Brossart P., Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells Blood 2004 103 2 538 544 (Pubitemid 38140084)
128. Appel S., Rupf A., Weck M. M., Schoor O., Brmmendorf T. H., Weinschenk T., Grnebach F., Brossart P., Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways Clinical Cancer Research 2005 11 5 1928 1940 (Pubitemid 40471859)
129. Wang H., Cheng F., Cuenca A., Horna P., Zheng Z., Bhalla K., Sotomayor E. M., Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance Blood 2005 105 3 1135 1143 (Pubitemid 40170886)
130. Borg C., Terme M., Taeb J., Ménard C., Flament C., Robert C., Maruyama K., Wakasugi H., Angevin E., Thielemans K., Le Cesne A., Chung-Scott V., Lazar V., Tchou I., Crépineau F., Lemoine F., Bernard J., Fletcher J. A., Turhan A., Blay J. Y., Spatz A., Emile J. F., Heinrich M. C., Mécheri S., Tursz T., Zitvogel L., Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects Journal of Clinical Investigation 2004 114 3 379 388 (Pubitemid 39071610)
131. Taieb J., Chaput N., Ménard C., Apetoh L., Ullrich E., Bonmort M., Péquignot M., Casares N., Terme M., Flament C., Opolon P., Lecluse Y., Métivier D., Tomasello E., Vivier E., Ghiringhelli F., Martin F., Klatzmann D., Poynard T., Tursz T., Raposo G., Yagita H., Ryffel B., Kroemer G., Zitvogel L., A novel dendritic cell subset involved in tumor immunosurveillance Nature Medicine 2006 12 2 214 219 (Pubitemid 43214748)
132. Chan G. W., Gorgun G., Miller K. B., Foss F. M., Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease Biology of Blood and Marrow Transplantation 2003 9 3 170 176
133. Deininger M., Buchdunger E., Druker B. J., The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood 2005 105 7 2640 2653 (Pubitemid 40446252)
134. Louvet C., Szot G. L., Lang J., Lee M. R., Martinier N., Bollag G., Zhu S., Weiss A., Bluestone J. A., Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice Proceedings of the National Academy of Sciences of the United States of America 2008 105 48 18895 18900
135. Shoda L. K. M., Young D. L., Ramanujan S., Whiting C. C., Atkinson M. A., Bluestone J. A., Eisenbarth G. S., Mathis D., Rossini A. A., Campbell S. E., Kahn R., Kreuwel H. T. C., A comprehensive review of interventions in the NOD mouse and implications for translation Immunity 2005 23 2 115 126 (Pubitemid 41169282)
136. Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., Izumi K., Sone S., Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice American Journal of Respiratory and Critical Care Medicine 2005 171 11 1279 1285 (Pubitemid 40740736)
137. Distler J. H. W., Jngel A., Huber L. C., Schulze-Horsel U., Zwerina J., Gay R. E., Michel B. A., Hauser T., Schett G., Gay S., Distler O., Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis and Rheumatism 2007 56 1 311 322 (Pubitemid 46106205)
138. Akhmetshina A., Dees C., Pileckyte M., Maurer B., Axmann R., Jngel A., Zwerina J., Gay S., Schett G., Distler O., Distler J. H. W., Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB Journal 2008 22 7 2214 2222 (Pubitemid 351948641)
139. Kamath A. V., Wang J., Lee F. Y., Marathe P. H., Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL Cancer Chemotherapy and Pharmacology 2008 61 365 376 (Pubitemid 350275972)
140. Kaur P., Feldhahn N., Zhang B., Trageser D., Mschen M., Pertz V., Groffen J., Heisterkamp N., Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia Molecular Cancer 2007 6, article 67
141. Luo F. R., Yang Z., Camuso A., Smykla R., McGlinchey K., Fager K., Flefleh C., Castaneda S., Inigo I., Kan D., Wen M. L., Kramer R., Blackwood-Chirchir A., Lee F. Y., Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure Clinical Cancer Research 2006 12 23 7180 7186 (Pubitemid 44974520)
142. Daniels C. E., Wikes M. C., Edens M., Imatinib mesylate inhibits the profibrogenic activity of TGF- and prevents bleomycin mediated lung fibrosis Journal of Clinical Investigation 2004 114 1308 1316 (Pubitemid 40385302)
143. Wang S., Wilkes M. C., Leof E. B., Hirschberg R., Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo FASEB Journal 2005 19 1 1 11 (Pubitemid 40069914)
144. Yoshiji H., Noguchi R., Kuriyama S., Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats AJPGastrointestinal and Liver Physiology 2005 288 G907 G913 (Pubitemid 40563130)
145. Leipner C., Grn K., Mller A., Buchdunger E., Borsi L., Kosmehl H., Berndt A., Janik T., Uecker A., Kiehntopf M., Bhmer F. D., Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis Cardiovascular Research 2008 79 1 118 126 (Pubitemid 351881931)
146. Gordon J., Spiera R., Imatinib and the treatment of fibrosis: recent trials and tribulations Current Rheumatology Reports 2011 13 51 58
147. Kay J., High W. A., Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis and Rheumatism 2008 58 8 2543 2548
148. Spiera R. F., Gordon J. K., Mersten J. N., Imatinib mesylate (gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial Annals of the Rheumatic Diseases 2011 70 1003 1009
149. Daniels C. E., Lasky J. A., Limper A. H., Mieras K., Gabor E., Schroeder D. R., Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results American Journal of Respiratory and Critical Care Medicine 2010 181 604 610
150. Shi Y., Massagué J., Mechanisms of TGF-beta signaling from cell membrane to the nucleus Cell 2003 113 6 685 700 (Pubitemid 36724933)
151. Trojanowska M., Noncanonical transforming growth factor beta signaling in scleroderma fibrosis Current Opinion in Rheumatology 2009 21 6 623 629
152. Iwamoto N., Distler J. H., Distler O., Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials Current Rheumatology Reports 2011 13 21 27
153. Pendergast A. M., The Abl family kinases: mechanisms of regulation and signaling Advances in Cancer Research 2002 85 51 100
154. Bhattacharyya S., Ishida W., Wu M., Wilkes M., Mori Y., Hinchcliff M., Leof E., Varga J., A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate Oncogene 2009 28 10 1285 1297
155. Pannu J., Asano Y., Nakerakanti S., Smith E., Jablonska S., Blaszczyk M., ten Dijke P., Trojanowska M., Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate Arthritis and Rheumatism 2008 58 8 2528 2537
156. Nakerakanti S. S., Bujor A. M., Trojanowska M., CCN2 is required for the TGF- induced activation of Smad1-Erk1/2 signaling network PLoS One 2011 6
157. Bujor A. M., Asano Y., Haines P., Lafyatis R., Trojanowska M., The c-Abl tyrosine kinase controls protein kinase C -induced Fli-1 phosphorylation in human dermal fibroblasts Arthritis Rheumatism 2011 63 1729 1737
158. Maurer B., Stanczyk J., Jngel A., Akhmetshina A., Trenkmann M., Brock M., Kowal-Bielecka O., Gay R. E., Michel B. A., Distler J. H. W., Gay S., Distler O., MicroRNA-29, a key regulator of collagen expression in systemic sclerosis Arthritis and Rheumatism 2010 62 6 1733 1743
159. Deininger M., Schleuning M., Greinix H., The effect of prior exposure to imatinib on transplant-related mortality Haematologica 2006 91 452 459
160. Giralt S. A., Arora M., Goldman J. M., Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia British Journal of Haematology 2007 137 461 467 (Pubitemid 46698285)
161. Oehler V. G., Gooley T., Snyder D. S., Johnston L., Lin A., Cummings C. C., Chu S., Bhatia R., Forman S. J., Negrin R. S., Appelbaum F. R., Radich J. P., The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood 2007 109 4 1782 1789 (Pubitemid 46239615)
162. Majhail N. S., Schiffer C. A., Weisdorf D. J., Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation Biology of Blood and Marrow Transplantation 2006 12 7 789 791 (Pubitemid 43899411)
163. Magro L., Catteau B., Coiteux V., Bruno B., Jouet J. P., Yakoub-Agha I., Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD Bone Marrow Transplantation 2008 42 11 757 760
164. Olivieri A., Locatelli F., Zecca M., Sanna A., Cimminiello M., Raimondi R., Gini G., Mordini N., Balduzzi A., Leoni P., Gabrielli A., Bacigalupo A., Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 2009 114 3 709 718
165. Magro L., Mohty M., Catteau B., Coiteux V., Chevallier P., Terriou L., Jouet J. P., Yakoub-Agha I., Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease Blood 2009 114 3 719 722
166. Stadler M., Ahlborn R., Kamal H., Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease Blood 2009 114 3718 3720
167. Rosti G., Palandri F., Castagnetti F., Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia Blood 2009 114 4933 4338
168. Fraser C. J., Baker K. S., The management and outcome of chronic graft-versus-host disease British Journal of Haematology 2007 138 2 131 145 (Pubitemid 46976332)